News UK grants patients early access to AbbVie/Roche leukaemia dr... Venetoclax still under review in Europe.
Clinical AbbVie/Roche's Venclexta produces complete remission in 10% ... AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
Views & Analysis Obstacles to true patient centricity in Europe Campaigner and cancer patient Andrew Schorr says pharma needs to knock down the barriers to greater patient influence.
News Novartis snaps up food allergy firm Excellergy for $2bn Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
